LAG3 and neoplasm: Moreover, upregulation of LAG-3 expression on tumor-infiltrating lymphocytes (TILs) has been suggested as a resistance marker to anti-programmed death 1 (anti-PD-1) treatment in patients who initially respond well to this treatment [8, 9].